查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561499

2024-2032 年按产品、组件、应用、最终用户和地区分類的重组 DNA 技术市场报告

Recombinant DNA Technology Market Report by Product, Component, Application, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球重组DNA技术市场IMARC Group达7,648亿美元。基因工程和生物技术的不断进步、对生物製药的需求不断增长、向个人化药物的日益转变以及慢性病患病率的上升主要推动了市场的成长。

重组DNA技术市场分析：

  • 主要市场驱动因素：改善不同健康状况的需求不断增长，加上诊断试剂盒、监测设备和新治疗方法的开发而改进的治疗策略，是推动市场成长的关键因素之一。
  • 主要市场趋势：快速的城市化、全球人口的成长、耕地的减少、粮食短缺的严重加剧以及基改作物的日益采用，正在不断增加市场需求。此外，重组DNA技术与有效基因疗法的整合，以正常基因取代缺陷基因，以及生产用于临床研究、研究和疾病诊断的抗原特异性抗体，预计将在未来几年推动市场成长。
  • 竞争格局：一些着名的重组DNA 技术市场公司包括Amgen Inc、Cibus、F.Hoffmann-La Roche Ltd、GenScript、GlaxoSmithKline plc.、Horizo​​​​n Discovery Group plc、Merck KGaA、New England Biolabs、Novo Nordisk A/ S、辉瑞公司、赛诺菲公司和 Syngene International Ltd (Biocon Limited) 等。
  • 地理趋势：根据重组DNA技术市场动态，在广泛的研发活动、完善的医疗基础设施和大量政府资助的推动下，北美在重组DNA技术市场中占有显着份额。此外，欧洲的成长得益于对研发的高度重视以及生物製药的高度采用。
  • 挑战与机会：监管合规性的提高和主要参与者之间的激烈竞争正在阻碍市场的成长。然而，对环保且省油的起落架系统的需求不断增加。製造商可以透过开发轻质材料和节能设计来利用这一趋势。

重组DNA技术市场趋势：

生物製药需求不断成长

对单株抗体、疫苗和胰岛素等生物製药的需求不断增长是一个主要驱动力。例如，根据IMARC Group的数据，2023 年全球生物製药市场规模将达到 3,005 亿美元。 2032.重组 DNA 技术在这些产品的生产中至关重要，这些产品对于治疗各种慢性疾病至关重要。这些因素预计将在未来几年推动重组 DNA 技术市场的发展。

慢性病盛行率增加

癌症、糖尿病和心血管疾病等慢性疾病的盛行率不断上升，是推动市场成长的重要因素之一。例如，根据 IDF 糖尿病地图集（2021 年），20 至 79 岁的成年人中有 10.5% 患有糖尿病。此外，到 2045 年，每 8 人中就有 1 人（约 7.83 亿人）患有糖尿病，增幅为 46%。重组 DNA 技术能够生产必需的治疗性蛋白质和激素，例如用于糖尿病管理的胰岛素和用于贫血治疗的促红血球生成素。这些因素进一步积极影响重组DNA技术产业市场。

技术进步

CRISPR等基因编辑工具的不断创新，正在提升重组DNA技术的精准度与应用范围，并推动市场扩张。例如，2024年8月，一群德国研究人员开发了一种增强型CRISPR（成簇规则间隔短回文重复）技术，以解决和改善针对血液和实体瘤的CAR-T细胞疗法中现有的障碍。 CRISPR 是一项独特的技术，使遗传学家和医学研究人员能够透过删除、插入或改变 DNA 序列来编辑基因组的部分，从而增加重组 DNA 技术系统的市场收入。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球重组 DNA 技术市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依产品

  • 医疗的
    • 市场趋势
    • 关键环节
      • 治疗剂
      • 人类蛋白质
      • 疫苗
    • 市场预测
  • 非医疗
    • 市场趋势
    • 关键环节
      • 生物技术作物
      • 特种化学品
      • 其他的
    • 市场预测

第 7 章：市场区隔：按组成部分

  • 表达系统
    • 市场趋势
    • 市场预测
  • 克隆载体
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按应用

  • 食品和农业
    • 市场趋势
    • 市场预测
  • 健康与疾病
    • 市场趋势
    • 市场预测
  • 环境
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 生物技术和製药公司
    • 市场趋势
    • 市场预测
  • 学术和政府研究机构
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc
    • Cibus
    • F.Hoffmann-La Roche Ltd
    • GenScript
    • GlaxoSmithKline plc.
    • Horizon Discovery Group plc
    • Merck KGaA
    • New England Biolabs
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi SA
    • Syngene International Ltd (Biocon Limited)
Product Code: SR112024A4484

The global recombinant DNA technology market size reached US$ 764.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,119.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032. The ongoing advancements in genetic engineering and biotechnology, the growing demand for biopharmaceuticals, increasing shift towards personalized medicines, and the rising prevalence of chronic diseases are primarily driving the market's growth.

Recombinant DNA Technology Market Analysis:

  • Major Market Drivers: The rising demand for improving different health conditions coupled with the improving treatment strategies on account of the developing diagnostics kits, monitoring devices, and new therapeutic approaches, represents one of the key factors impelling the growth of the market.
  • Key Market Trends: Rapid urbanization, growing global population, reducing arable land, considerable rising food shortage, and increasing adoption of GMO crops, are escalating the market demand. In addition, the integration of recombinant DNA technology with effective gene therapy for replacing defective genes with normal ones and the production of antigen-specific antibodies for clinical research, studies, and disease diagnosis, are anticipated to drive the market growth in the upcoming years.
  • Competitive Landscape: Some of the prominent recombinant DNA technology market companies include Amgen Inc, Cibus, F.Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline plc., Horizon Discovery Group plc, Merck KGaA, New England Biolabs, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A, and Syngene International Ltd (Biocon Limited), among many others.
  • Geographical Trends: According to the recombinant DNA technology market dynamics, North America holds a prominent share in the recombinant DNA technology market, driven by extensive research and development activities, well-established healthcare infrastructure, and significant government funding. Moreover, the growth in Europe is supported by a strong focus on research and development and high adoption of biopharmaceuticals.
  • Challenges and Opportunities: Rising regulatory compliances and high competition among key players are hampering the market growth. However, there is an increasing demand for environmentally friendly and fuel-efficient landing gear systems. Manufacturers can capitalize on this trend by developing lightweight materials and energy-efficient designs.

Recombinant DNA Technology Market Trends:

Rising Demand for Biopharmaceuticals

The rising demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and insulin, is a major driver. For instance, according to IMARC, the global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. Recombinant DNA technology is pivotal in the production of these products, which are essential for treating various chronic diseases. These factors are expected to propel the recombinant DNA technology market in the coming years.

Increasing Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases, is one of the significant factors driving the market's growth. For instance, according to the IDF Diabetes Atlas (2021), 10.5% of adults aged 20 to 79 suffer from diabetes. Also, by 2045, one in every eight persons, or roughly 783 million, will have diabetes, representing a 46% rise. Recombinant DNA technology enables the production of essential therapeutic proteins and hormones, such as insulin for diabetes management and erythropoietin for anemia treatment. These factors are further positively influencing the recombinant DNA technology industry market.

Technological Advancements

Continuous technological innovations, such as CRISPR and other gene-editing tools, are enhancing the precision and application scope of recombinant DNA technology, driving the market expansion. For instance, in August 2024, a group of German researchers developed an enhanced CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technique to solve and improve existing obstacles in CAR-T cell therapy that targets both blood and solid tumors. CRISPR is a unique technology that enables geneticists and medical researchers to edit portions of the genome by removing, inserting, or changing DNA sequences, thereby boosting the recombinant DNA technology systems market revenue.

Global Recombinant DNA Technology Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global recombinant DNA technology market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, component, application, and end user.

Breakup by Product:

  • Medical
    • Therapeutic Agent
    • Human Protein
    • Vaccines
  • Non-Medical
    • Biotech Crops
    • Specialty Chemicals
    • Others

The report has provided a detailed breakup and analysis of the recombinant DNA technology market based on the product. This includes medical (therapeutic agent, human protein, and vaccines), and non-medical (biotech crops, specialty chemicals, and others).

According to the recombinant DNA technology market outlook, recombinant DNA technology enables the development of gene therapies to treat genetic disorders like cystic fibrosis, hemophilia, and muscular dystrophy. This technology has revolutionized the production of human insulin, making it more accessible for diabetic patients. While crops like Bt cotton, Roundup Ready soybeans, and Golden Rice have been developed using rDNA technology to enhance resistance to pests, herbicides, and to improve nutritional content.

Breakup by Component:

  • Expression System
  • Cloning Vector

The report has provided a detailed breakup and analysis of the recombinant DNA technology market based on the component. This includes expression system and cloning vector.

According to the recombinant DNA technology market overview, an expression system refers to the host organism and the molecular machinery used to produce recombinant proteins. It includes the host cells, the vectors, and the regulatory sequences necessary for gene expression. While a cloning vector is a DNA molecule used to carry foreign genetic material into a host cell, where it can be replicated and/or expressed. It is used in the development of genetically modified crops with desirable traits such as pest resistance and improved nutritional content.

Breakup by Application:

  • Food and Agriculture
  • Health and Disease
  • Environment
  • Others

A detailed breakup and analysis of the recombinant DNA technology market based on application has also been provided in the report. This includes food and agriculture, health and disease, environment, and others.

Recombinant DNA technology is used to develop genetically modified (GM) crops with desirable traits such as increased yield, pest resistance, herbicide tolerance, and improved nutritional content. This is crucial for meeting the food demands of a growing global population. Apart from this, in health and disease, it enables the production of insulin, growth hormones, monoclonal antibodies, and vaccines. The demand for effective and affordable biopharmaceuticals drives this sector. Besides this, it is also used to engineer microorganisms that can break down pollutants and toxins in the environment. This helps in cleaning up oil spills, heavy metals, and other environmental contaminants.

Breakup by End User:

  • Biotechnology and Pharmaceutical Companies
  • Academic and Government Research Institutes
  • Others

A detailed breakup and analysis of the recombinant DNA technology market based on end user has also been provided in the report. This includes biotechnology and pharmaceutical companies, academic and government research institutes, and others.

In biotechnology and pharmaceutical companies, recombinant DNA technology is used to produce human insulin in bacteria, which is a major advancement over previous methods using animal insulin. Companies use rDNA to develop monoclonal antibodies for the treatment of various diseases, including cancer and autoimmune disorders. While government research institutes like the CDC use rDNA technology to monitor and study pathogens, enabling rapid response to outbreaks and epidemics.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

According to the recombinant DNA technology market statistics, North America is one of the prominent regions for rDNA technology due to significant investments in biotechnology and pharmaceuticals. Moreover, Europe has a well-established biotechnology sector, particularly in countries like Germany, France, and the UK. The growth of the European region is driven by the strong collaboration between academic institutions, research institutes, and industry.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Amgen Inc
  • Cibus
  • F.Hoffmann-La Roche Ltd
  • GenScript
  • GlaxoSmithKline plc.
  • Horizon Discovery Group plc
  • Merck KGaA
  • New England Biolabs
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi S.A
  • Syngene International Ltd (Biocon Limited)

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Recombinant DNA Technology Market Recent Developments:

  • August 2024: German researchers developed an enhanced CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technique to solve and improve existing obstacles in CAR-T cell therapy that targets both blood and solid tumors.
  • July 2024: Scientists at the CSIR-Institute of Genomics and Integrative Biology in New Delhi developed an upgraded genome-editing device that can modify DNA more precisely and efficiently.
  • February 2024: Belgian researchers from the VIB-KU Leuven Center for Microbiology and the VIB-UGent Center for Plant Systems Biology created a new toolbox comprising 16 different short DNA sequences that may initiate controlled and selective recombination processes in any genome.

Key Questions Answered in This Report:

  • How has the global recombinant DNA technology market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global recombinant DNA technology market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the component?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global recombinant DNA technology market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Recombinant DNA Technology Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Medical
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Therapeutic Agent
      • 6.1.2.2 Human Protein
      • 6.1.2.3 Vaccines
    • 6.1.3 Market Forecast
  • 6.2 Non-Medical
    • 6.2.1 Market Trends
    • 6.2.2 Key Segments
      • 6.2.2.1 Biotech Crops
      • 6.2.2.2 Specialty Chemicals
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Component

  • 7.1 Expression System
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cloning Vector
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Food and Agriculture
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Health and Disease
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Environment
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Biotechnology and Pharmaceutical Companies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Academic and Government Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Amgen Inc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Cibus
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 F.Hoffmann-La Roche Ltd
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 GenScript
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 GlaxoSmithKline plc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Horizon Discovery Group plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 New England Biolabs
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Novo Nordisk A/S
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi S.A
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Syngene International Ltd (Biocon Limited)
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Recombinant DNA Technology Market: Major Drivers and Challenges
  • Figure 2: Global: Recombinant DNA Technology Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Recombinant DNA Technology Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Recombinant DNA Technology Market: Breakup by Product (in %), 2023
  • Figure 5: Global: Recombinant DNA Technology Market: Breakup by Component (in %), 2023
  • Figure 6: Global: Recombinant DNA Technology Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Recombinant DNA Technology Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Recombinant DNA Technology Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Recombinant DNA Technology (Medical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Recombinant DNA Technology (Medical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Recombinant DNA Technology (Non-Medical) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Recombinant DNA Technology (Non-Medical) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Recombinant DNA Technology (Expression System) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Recombinant DNA Technology (Expression System) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Recombinant DNA Technology (Cloning Vector) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Recombinant DNA Technology (Cloning Vector) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Recombinant DNA Technology (Food and Agriculture) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Recombinant DNA Technology (Food and Agriculture) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Recombinant DNA Technology (Health and Disease) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Recombinant DNA Technology (Health and Disease) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Recombinant DNA Technology (Environment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Recombinant DNA Technology (Environment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Recombinant DNA Technology (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Recombinant DNA Technology (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Recombinant DNA Technology (Biotechnology and Pharmaceutical Companies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Recombinant DNA Technology (Biotechnology and Pharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Recombinant DNA Technology (Academic and Government Research Institutes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Recombinant DNA Technology (Academic and Government Research Institutes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Recombinant DNA Technology (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Recombinant DNA Technology (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: North America: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: North America: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: United States: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: United States: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Canada: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Canada: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Asia-Pacific: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Asia-Pacific: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: China: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: China: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Japan: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Japan: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: India: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: India: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: South Korea: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: South Korea: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Australia: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Australia: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Indonesia: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Indonesia: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: Others: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Europe: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Europe: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Germany: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Germany: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: France: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: France: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: United Kingdom: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: United Kingdom: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Italy: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Italy: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Spain: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Spain: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Russia: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Russia: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Latin America: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Latin America: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Brazil: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Brazil: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Mexico: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Mexico: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Others: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Others: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Middle East and Africa: Recombinant DNA Technology Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Middle East and Africa: Recombinant DNA Technology Market: Breakup by Country (in %), 2023
  • Figure 79: Middle East and Africa: Recombinant DNA Technology Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Global: Recombinant DNA Technology Industry: SWOT Analysis
  • Figure 81: Global: Recombinant DNA Technology Industry: Value Chain Analysis
  • Figure 82: Global: Recombinant DNA Technology Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Recombinant DNA Technology Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Recombinant DNA Technology Market Forecast: Breakup by Product (in Million US$), 2024-2032
  • Table 3: Global: Recombinant DNA Technology Market Forecast: Breakup by Component (in Million US$), 2024-2032
  • Table 4: Global: Recombinant DNA Technology Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Recombinant DNA Technology Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Recombinant DNA Technology Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Recombinant DNA Technology Market: Competitive Structure
  • Table 8: Global: Recombinant DNA Technology Market: Key Players